

Heather Hampel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1225176/publications.pdf>

Version: 2024-02-01

214
papers

20,394
citations

11651

70
h-index

11052

137
g-index

224
all docs

224
docs citations

224
times ranked

16348
citing authors

#	ARTICLE	IF	CITATIONS
1	Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake. <i>Familial Cancer</i> , 2023, 22, 91-97.	1.9	6
2	Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. <i>Journal of Medical Genetics</i> , 2022, 59, 318-327.	3.2	57
3	American Gastroenterological Association Institute and College of American Pathologists Quality Measure Development for Detection of Mismatch Repair Deficiency and Lynch Syndrome Management. <i>Gastroenterology</i> , 2022, 162, 360-365.	1.3	4
4	Microsatellite instability in young patients with rectal cancer: molecular findings and treatment response. <i>British Journal of Surgery</i> , 2022, 109, 251-255.	0.3	9
5	Prevalence and Predictors of Young-Onset Colorectal Neoplasia: Insights From a Nationally Representative Colonoscopy Registry. <i>Gastroenterology</i> , 2022, 162, 1136-1146.e5.	1.3	14
6	Risk assessment and genetic counseling for Lynch syndrome – Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. <i>Journal of Genetic Counseling</i> , 2022, 31, 568-583.	1.6	7
7	Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis. <i>PLoS Medicine</i> , 2022, 19, e1003897.	8.4	30
8	Impact of microsatellite status in early-onset colonic cancer. <i>British Journal of Surgery</i> , 2022, 109, 632-636.	0.3	7
9	Differences in somatic TP53 mutation type in breast tumors by race and receptor status. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 639-648.	2.5	7
10	Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1077-1089.	2.5	6
11	Genetic Regulation of DNA Methylation Yields Novel Discoveries in GWAS of Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1068-1076.	2.5	1
12	Hereditary Colorectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 429-447.	2.2	14
13	Utilizing Public Health Frameworks and Partnerships to Ensure Equity in DNA-Based Population Screening. <i>Frontiers in Genetics</i> , 2022, 13, .	2.3	2
14	Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients. <i>Cancers</i> , 2022, 14, 2426.	3.7	3
15	Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?. <i>Journal of Clinical Oncology</i> , 2022, 40, 2681-2692.	1.6	18
16	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> , 2021, 160, 1164-1178.e6.	1.3	36
17	A High Percentage of Early-age Onset Colorectal Cancer Is Potentially Preventable. <i>Gastroenterology</i> , 2021, 160, 1850-1852.	1.3	19
18	Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. <i>Gynecologic Oncology</i> , 2021, 160, 161-168.	1.4	24

#	ARTICLE	IF	CITATIONS
19	Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1490-1502.	4.7	27
20	Genetic architectures of proximal and distal colorectal cancer are partly distinct. <i>Gut</i> , 2021, 70, 1325-1334.	12.1	44
21	Albert de la Chapelle (1933–2020). <i>American Journal of Human Genetics</i> , 2021, 108, 214-216.	6.2	0
22	Response to Li and Hopper. <i>American Journal of Human Genetics</i> , 2021, 108, 527-529.	6.2	5
23	Stakeholders'™ views of integrating universal tumour screening and genetic testing for colorectal and endometrial cancer into routine oncology. <i>European Journal of Human Genetics</i> , 2021, 29, 1634-1644.	2.8	6
24	Many Polyps but Few Referrals: A Call to Assess and Improve Referral Rates for Colon Polyposis. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 1035-1037.	1.3	0
25	Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. <i>JCO Precision Oncology</i> , 2021, 5, 779-791.	3.0	31
26	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 1014-1022.	10.7	58
27	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. <i>Journal of Clinical Oncology</i> , 2021, 39, 2779-2790.	1.6	40
28	Characteristics of Early-Onset vs Late-Onset Colorectal Cancer. <i>JAMA Surgery</i> , 2021, 156, 865.	4.3	110
29	Advanced adenomas may be a red flag for hereditary cancer syndromes. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 8.	1.5	2
30	Early age onset colorectal cancer. <i>Advances in Cancer Research</i> , 2021, 151, 1-37.	5.0	15
31	A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 564-575.	2.5	10
32	Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study. <i>JCO Precision Oncology</i> , 2021, 5, 1588-1602.	3.0	15
33	Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study. <i>Nutrients</i> , 2021, 13, 4164.	4.1	3
34	Economic Evaluation of Universal Lynch Syndrome Screening Protocols among Newly Diagnosed Patients with Colorectal Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 1284.	2.5	6
35	NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1122-1132.	4.9	68
36	Cumulative Burden of Colorectal Cancer–Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. <i>Gastroenterology</i> , 2020, 158, 1274-1286.e12.	1.3	110

#	ARTICLE	IF	CITATIONS
37	Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses. <i>Gastroenterology</i> , 2020, 158, 1300-1312.e20.	1.3	90
38	Tumor Budding Detection System in Whole Slide Pathology Images. <i>Journal of Medical Systems</i> , 2020, 44, 38.	3.6	11
39	Implementing universal cancer screening programs can help sustain genomic medicine programs. <i>Personalized Medicine</i> , 2020, 17, 9-13.	1.5	1
40	MSH6 immunohistochemical heterogeneity in colorectal cancer: comparative sequencing from different tumor areas. <i>Human Pathology</i> , 2020, 96, 104-111.	2.0	17
41	Patterns of Early-Onset Colorectal Cancer Among Nigerians and African Americans. <i>JCO Global Oncology</i> , 2020, 6, 1647-1655.	1.8	11
42	Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 432-444.	6.2	124
43	Intake of Dietary Fruit, Vegetables, and Fiber and Risk of Colorectal Cancer According to Molecular Subtypes: A Pooled Analysis of 9 Studies. <i>Cancer Research</i> , 2020, 80, 4578-4590.	0.9	26
44	Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. <i>BMC Medicine</i> , 2020, 18, 396.	5.5	76
45	Hemochromatosis risk genotype is not associated with colorectal cancer or age at its diagnosis. <i>Human Genetics and Genomics Advances</i> , 2020, 1, 100010.	1.7	3
46	Comparative Effectiveness of Two Interventions to Increase Colorectal Cancer Screening for Those at Increased Risk Based on Family History: Results of a Randomized Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 3-9.	2.5	9
47	Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. <i>Familial Cancer</i> , 2020, 19, 223-239.	1.9	39
48	Unexpected expression of mismatch repair protein is more commonly seen with pathogenic missense than with other mutations in Lynch syndrome. <i>Human Pathology</i> , 2020, 103, 34-41.	2.0	14
49	Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. <i>Nature Communications</i> , 2020, 11, 597.	12.8	193
50	What guidance does HIPAA offer to providers considering familial risk notification and cascade genetic testing?. <i>Journal of Law and the Biosciences</i> , 2020, 7, lsaa071.	1.6	17
51	Stakeholder Perspectives on Overcoming Barriers to Cascade Testing in Lynch Syndrome: A Qualitative Study. <i>Cancer Prevention Research</i> , 2020, 13, 1037-1046.	1.5	12
52	Lynch Syndrome: Management of the Colon, What Operation?. , 2020, , 149-174.		1
53	Tumor Budding Detection in H&E-Stained Images Using Deep Semantic Learning. , 2020, , .		0
54	Modified capture-recapture estimates of the number of families with Lynch syndrome in Central Ohio. <i>Familial Cancer</i> , 2019, 18, 67-73.	1.9	7

#	ARTICLE	IF	CITATIONS
55	A Summary of the Fight Colorectal Cancer Working Meeting: Exploring Risk Factors and Etiology of Sporadic Early-Age Onset Colorectal Cancer. <i>Gastroenterology</i> , 2019, 157, 280-288.	1.3	32
56	Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000299.	2.7	9
57	Hereditary Colorectal Cancer Syndromes. <i>Seminars in Oncology Nursing</i> , 2019, 35, 58-78.	1.5	15
58	“Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome” reply. <i>Human Pathology</i> , 2019, 89, 116-117.	2.0	0
59	Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome. <i>Journal of Medical Genetics</i> , 2019, 56, 462-470.	3.2	61
60	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. <i>Genetics in Medicine</i> , 2019, 21, 2390-2400.	2.4	153
61	Prevalence of Germline Mutations in Polyposis and Colorectal Cancer-Associated Genes in Patients With Multiple Colorectal Polyps. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2008-2015.e3.	4.4	43
62	Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. <i>International Journal of Cancer</i> , 2019, 144, 2161-2168.	5.1	34
63	Discovery of common and rare genetic risk variants for colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 76-87.	21.4	377
64	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1032-1041.	4.9	191
65	A phase II study of PD-1 inhibition for the prevention of colon adenomas in patients with Lynch syndrome and a history of partial colectomy. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS1587-TPS1587.	1.6	1
66	Low Prevalence of Gastric and Duodenal Neoplasia in Patients With Colon Polyposis of Unknown Etiology. <i>American Journal of Gastroenterology</i> , 2019, 114, S136-S136.	0.4	0
67	Population Screening for Hereditary Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 319-325.	1.5	15
68	Colorectal Carcinomas With Isolated Loss of PMS2 Staining by Immunohistochemistry. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 523-528.	2.5	22
69	Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome. <i>Human Pathology</i> , 2018, 78, 125-130.	2.0	28
70	Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 806.	7.1	136
71	Penetrance of a rare familial mutation predisposing to papillary thyroid cancer. <i>Familial Cancer</i> , 2018, 17, 431-434.	1.9	7
72	Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 101-109.	3.8	73

#	ARTICLE	IF	CITATIONS
73	Cancer Risks for <i>PMS2</i> -Associated Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2018, 36, 2961-2968.	1.6	147
74	Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop. <i>Public Health Genomics</i> , 2018, 21, 121-132.	1.0	20
75	Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency. <i>Modern Pathology</i> , 2018, 31, 1891-1900.	5.5	57
76	Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The Literature. <i>Health Affairs</i> , 2018, 37, 801-808.	5.2	114
77	NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 939-949.	4.9	116
78	Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes. <i>American Journal of Human Genetics</i> , 2018, 103, 19-29.	6.2	36
79	Screening for Pancreatic Cancer: <i>Who to Screen and How to Follow-Up?</i> . , 2018, , 97-108.		0
80	Beyond BRCA1/2: Clinician-reported utility 3 years post panel testing.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18705-e18705.	1.6	0
81	Lynch Syndrome Limbo: Patient Understanding of Variants of Uncertain Significance. <i>Journal of Genetic Counseling</i> , 2017, 26, 866-877.	1.6	50
82	Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. <i>Nature Communications</i> , 2017, 8, 14755.	12.8	96
83	Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, 464.	7.1	510
84	Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. <i>Gynecologic Oncology</i> , 2017, 146, 588-595.	1.4	77
85	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1465-1475.	4.9	109
86	Mutation Frequencies in Patients With Early-Onset Colorectal Cancer—Reply. <i>JAMA Oncology</i> , 2017, 3, 1587.	7.1	5
87	Multigene Panel Testing Provides a New Perspective on Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2017, 35, 2568-2575.	1.6	122
88	Variable DNA mismatch repair-associated gene profiles in colorectal versus uterine cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11610-11610.	1.6	0
89	Prevalence of Mutations in Adenomatous Polyposis and Colorectal Cancer-Associated Genes in Patients With Multiple Colon Polyps Stratified by Age. <i>American Journal of Gastroenterology</i> , 2017, 112, S46-S47.	0.4	0
90	Discordant Mismatch Repair Protein Immunoreactivity in Lynch Syndrome—Associated Neoplasms. <i>American Journal of Clinical Pathology</i> , 2016, 146, 50-56.	0.7	24

#	ARTICLE	IF	CITATIONS
91	Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1010-1030.	4.9	179
92	Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis. Familial Cancer, 2016, 15, 253-260.	1.9	36
93	Using Genetic Technologies To Reduce, Rather Than Widen, Health Disparities. Health Affairs, 2016, 35, 1367-1373.	5.2	67
94	Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A state-of-the-science review. Cancer, 2016, 122, 2633-2645.	4.1	131
95	MSH6 and PMS2 Mutation Carriers Ascertained Through Multi-gene Panel Testing May Present With a Hereditary Breast and Ovarian Cancer Phenotype. Gynecologic Oncology, 2016, 143, 194.	1.4	1
96	Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. Gastroenterology, 2016, 151, 440-447.e1.	1.3	36
97	Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. Genetics in Medicine, 2016, 18, 863-868.	2.4	30
98	Improving performance of multigene panels for genomic analysis of cancer predisposition. Genetics in Medicine, 2016, 18, 974-981.	2.4	80
99	Genetic counseling and cascade genetic testing in Lynch syndrome. Familial Cancer, 2016, 15, 423-427.	1.9	84
100	Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	6.3	29
101	PMS2 monoallelic mutation carriers: the known unknown. Genetics in Medicine, 2016, 18, 13-19.	2.4	51
102	Qualitative Comparative Analysis. Journal of Mixed Methods Research, 2016, 10, 251-272.	2.6	57
103	Comprehensive population-wide detection of Lynch syndrome in Iceland.. Journal of Clinical Oncology, 2016, 34, 1542-1542.	1.6	3
104	Deletions in HSP110 T17 and patient prognosis in stage III microsatellite instable (MSI) colon cancers: Findings from CALGB 89803 and NCCTG N0147.. Journal of Clinical Oncology, 2016, 34, e15148-e15148.	1.6	0
105	Colorectal Cancer Screening, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 959-968.	4.9	80
106	Allele-specific imbalance mapping at human orthologs of mouse susceptibility to colon cancer (<i>Scc</i>) loci. International Journal of Cancer, 2015, 137, 2323-2331.	5.1	5
107	Creation of a Network to Promote Universal Screening for Lynch Syndrome: The Lynch Syndrome Screening Network. Journal of Genetic Counseling, 2015, 24, 421-427.	1.6	28
108	Use of Whole Genome Sequencing for Diagnosis and Discovery in the Cancer Genetics Clinic. EBioMedicine, 2015, 2, 74-81.	6.1	50

#	ARTICLE	IF	CITATIONS
109	A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. <i>Genetics in Medicine</i> , 2015, 17, 70-87.	2.4	418
110	A Modified Lynch Syndrome Screening Algorithm in Colon Cancer. <i>American Journal of Clinical Pathology</i> , 2015, 143, 336-343.	0.7	27
111	ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. <i>American Journal of Gastroenterology</i> , 2015, 110, 223-262.	0.4	1,204
112	Mutation Spectrum and Risk of Colorectal Cancer in African American Families with Lynch Syndrome. <i>Gastroenterology</i> , 2015, 149, 1446-1453.	1.3	46
113	The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates. <i>Genetics in Medicine</i> , 2015, 17, 510-511.	2.4	30
114	Preliminary validation of a consumer-oriented colorectal cancer risk assessment tool compatible with the US Surgeon General's My Family Health Portrait. <i>Genetics in Medicine</i> , 2015, 17, 753-756.	2.4	13
115	Certified Genetic Counselors. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 653-666.	1.5	6
116	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. <i>Journal of Clinical Oncology</i> , 2015, 33, 3660-3667.	1.6	603
117	Combined Microsatellite Instability, <i>MLH1</i> Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4301-4308.	1.6	163
118	Sarcoma: A Lynch syndrome (LS)-associated malignancy?. <i>Journal of Clinical Oncology</i> , 2015, 33, 1516-1516.	1.6	6
119	<i>PIK3CA</i> mutations in colorectal and endometrial cancer with double somatic mismatch repair mutations compared to Lynch syndrome.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3550-3550.	1.6	4
120	Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through. <i>Genetics in Medicine</i> , 2014, 16, 773-782.	2.4	62
121	Prostate cancer incidence in males with Lynch syndrome. <i>Genetics in Medicine</i> , 2014, 16, 553-557.	2.4	88
122	Microsatellite Instability Detection by Next Generation Sequencing. <i>Clinical Chemistry</i> , 2014, 60, 1192-1199.	3.2	333
123	Biallelic <i>MUTYH</i> mutations can mimic Lynch syndrome. <i>European Journal of Human Genetics</i> , 2014, 22, 1334-1337.	2.8	87
124	Colon and Endometrial Cancers With Mismatch Repair Deficiency Can Arise From Somatic, Rather Than Germline, Mutations. <i>Gastroenterology</i> , 2014, 147, 1308-1316.e1.	1.3	328
125	NCCN Increases the Emphasis on Genetic/Familial High-Risk Assessment in Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 829-831.	4.9	35
126	Effect of genetic counseling on detection of Lynch syndrome (LS) in colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 419-419.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Universal screening for Lynch syndrome (LS) in colorectal cancer (CRC) and survival.. Journal of Clinical Oncology, 2014, 32, 415-415.	1.6	1
128	Immunodepletion Plasma Proteomics by TripleTOF 5600 and Orbitrap Elite/LTQ-Orbitrap Velos/Q Exactive Mass Spectrometers. Journal of Proteome Research, 2013, 12, 4351-4365.	3.7	43
129	BRAF V600E Mutation Analysis Simplifies the Testing Algorithm for Lynch Syndrome. American Journal of Clinical Pathology, 2013, 140, 177-183.	0.7	46
130	Analysis of Induced Pluripotent Stem Cells from a BRCA1 Mutant Family. Stem Cell Reports, 2013, 1, 336-349.	4.8	40
131	How do we approach the goal of identifying everybody with Lynch Syndrome?. Familial Cancer, 2013, 12, 313-317.	1.9	58
132	Phosphatase and Tensin Homolog Immunohistochemical Staining and Clinical Criteria for Cowden Syndrome in Patients With Trichilemmoma or Associated Lesions. American Journal of Dermatopathology, 2013, 35, 637-640.	0.6	18
133	Mismatch Repair Protein Deficiency is Common in Sebaceous Neoplasms and Suggests the Importance of Screening for Lynch Syndrome. American Journal of Dermatopathology, 2013, 35, 191-195.	0.6	27
134	Colorectal Cancer Screening. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1538-1575.	4.9	82
135	Prostate cancer incidence in males with Lynch syndrome.. Journal of Clinical Oncology, 2013, 31, 366-366.	1.6	1
136	Differences in outcome between colorectal cancer (CRC) patients (pts) with Lynch syndrome (LS) versus MLH1 hypermethylation (MLH1 HM).. Journal of Clinical Oncology, 2013, 31, 1556-1556.	1.6	0
137	Cancer risks and mutation spectrum of mismatch repair genes in African American families with Lynch syndrome.. Journal of Clinical Oncology, 2013, 31, 1530-1530.	1.6	8
138	Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genetics in Medicine, 2012, 14, 670-680.	2.4	40
139	Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genetics in Medicine, 2012, 14, 152-162.	2.4	83
140	Characterization of the colorectal cancer-associated enhancer MYC-335 at 8q24: the role of rs67491583. Cancer Genetics, 2012, 205, 25-33.	0.4	24
141	Identification of Lynch Syndrome Among Patients With Colorectal Cancer. JAMA - Journal of the American Medical Association, 2012, 308, 1555.	7.4	443
142	Mismatch repair analysis of inherited MSH2 and/or MSH6 variation pairs found in cancer patients. Human Mutation, 2012, 33, 1294-1301.	2.5	13
143	Identification of Individuals at Risk for Lynch Syndrome Using Targeted Evaluations and Genetic Testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline. Journal of Genetic Counseling, 2012, 21, 484-493.	1.6	119
144	An American founder mutation in <i>MLH1</i>. International Journal of Cancer, 2012, 130, 2088-2095.	5.1	12

#	ARTICLE	IF	CITATIONS
145	Transition to the Clinical Doctorate: Attitudes of the Genetic Counseling Training Program Directors in North America. <i>Journal of Genetic Counseling</i> , 2012, 21, 136-149.	1.6	3
146	Evaluation of Allele-Specific Somatic Changes of Genome-Wide Association Study Susceptibility Alleles in Human Colorectal Cancers. <i>PLoS ONE</i> , 2012, 7, e37672.	2.5	8
147	Abstract 28: The Netrin-1 receptor UNC5C is a tumor suppressor in colorectal malignancies. , 2012, , .		0
148	Variants in the Netrin-1 Receptor UNC5C Prevent Apoptosis and Increase Risk of Familial Colorectal Cancer. <i>Gastroenterology</i> , 2011, 141, 2039-2046.	1.3	28
149	Compliance with recommended genetic counseling for Lynch syndrome: Room for improvement. <i>Gynecologic Oncology</i> , 2011, 120, S58-S59.	1.4	0
150	Endometrial cancer patients and compliance with genetic counseling: Room for improvement. <i>Gynecologic Oncology</i> , 2011, 123, 532-536.	1.4	40
151	The Search for Unaffected Individuals with Lynch Syndrome: Do the Ends Justify the Means?. <i>Cancer Prevention Research</i> , 2011, 4, 1-5.	1.5	138
152	Point: Justification for Lynch Syndrome Screening Among All Patients With Newly Diagnosed Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 597-601.	4.9	56
153	Genetic/Familial High-Risk Assessment: Breast and Ovarian. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 562-594.	4.9	253
154	Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study. <i>International Journal of Colorectal Disease</i> , 2010, 25, 703-712.	2.2	48
155	Clinical Relevance of Microsatellite Instability in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3380-3387.	1.6	273
156	Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2010, 102, 193-201.	6.3	328
157	Allele-specific expression of TGFBR1 in colon cancer patients. <i>Carcinogenesis</i> , 2010, 31, 1800-1804.	2.8	18
158	The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. <i>Genetics in Medicine</i> , 2010, 12, 93-104.	2.4	250
159	Reply to L.H. Jensen et al and S. Jahn et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e225-e225.	1.6	1
160	Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer. <i>Genetics in Medicine</i> , 2009, 11, 812-817.	2.4	45
161	EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. <i>Genetics in Medicine</i> , 2009, 11, 42-65.	2.4	431
162	Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. <i>Gynecologic Oncology</i> , 2009, 114, 128-134.	1.4	97

#	ARTICLE	IF	CITATIONS
163	Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. <i>Gynecologic Oncology</i> , 2009, 114, 486-490.	1.4	68
164	Identifying Lynch syndrome. <i>International Journal of Cancer</i> , 2009, 125, 1492-1493.	5.1	32
165	Are prediction models for Lynch syndrome valid for probands with endometrial cancer?. <i>Familial Cancer</i> , 2009, 8, 483-487.	1.9	14
166	Genetic Counseling Practice Analysis. <i>Journal of Genetic Counseling</i> , 2009, 18, 205-216.	1.6	26
167	Recontacting Patients Who have Tested Negative for <i>BRCA1</i> and <i>BRCA2</i> Mutations: How, Who and Why?. <i>Journal of Genetic Counseling</i> , 2009, 18, 527-529.	1.6	10
168	Genetic Testing for Hereditary Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2009, 18, 687-703.	1.5	22
169	Lynch Syndrome Screening Strategies Among Newly Diagnosed Endometrial Cancer Patients. <i>Obstetrics and Gynecology</i> , 2009, 114, 530-536.	2.4	62
170	Screen positive rates among six family history screening protocols for breast/ovarian cancer in four cohorts of women. <i>Familial Cancer</i> , 2008, 7, 341-345.	1.9	9
171	Genotyping panel for assessing response to cancer chemotherapy. <i>BMC Medical Genomics</i> , 2008, 1, 24.	1.5	24
172	The Clinical Phenotype of Lynch Syndrome Due to Germ-Line PMS2 Mutations. <i>Gastroenterology</i> , 2008, 135, 419-428.e1.	1.3	480
173	Germline Allele-Specific Expression of <i>TGFBR1</i> Confers an Increased Risk of Colorectal Cancer. <i>Science</i> , 2008, 321, 1361-1365.	12.6	157
174	Origins and Prevalence of the American Founder Mutation of <i>MSH2</i> . <i>Cancer Research</i> , 2008, 68, 2145-2153.	0.9	34
175	Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5783-5788.	1.6	760
176	A frame-shift mutation of PMS2 is a widespread cause of Lynch syndrome. <i>Journal of Medical Genetics</i> , 2008, 45, 340-345.	3.2	47
177	The Frequency of Muir-Torre Syndrome Among Lynch Syndrome Families. <i>Journal of the National Cancer Institute</i> , 2008, 100, 277-281.	6.3	152
178	Prospective Evaluation of Mismatch Repair Protein Expression in Primary Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2008, 103, S169-S170.	0.4	0
179	Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. <i>Cancer Research</i> , 2007, 67, 9603-9603.	0.9	88
180	Evidence for heritable predisposition to epigenetic silencing of MLH1. <i>International Journal of Cancer</i> , 2007, 120, 1684-1688.	5.1	75

#	ARTICLE	IF	CITATIONS
181	Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. <i>Cancer Research</i> , 2006, 66, 7810-7817.	0.9	564
182	Pathogenicity of MSH2 Missense Mutations Is Typically Associated With Impaired Repair Capability of the Mutated Protein. <i>Gastroenterology</i> , 2006, 131, 1408-1417.	1.3	59
183	Histologic features distinguish microsatellite-high from microsatellite-low and microsatellite-stable colorectal carcinomas, but do not differentiate germline mutations from methylation of the MLH1 promoter. <i>Human Pathology</i> , 2006, 37, 831-838.	2.0	49
184	Improved Survival With an Intact DNA Mismatch Repair System in Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2006, 108, 1208-1215.	2.4	56
185	Utilization of genetic counseling services by surgical oncologists: education a must. <i>Clinical Genetics</i> , 2006, 70, 524-525.	2.0	1
186	American founder mutation for Lynch syndrome. <i>Cancer</i> , 2006, 106, 448-452.	4.1	16
187	Long-range PCR facilitates the identification of PMS2-specific mutations. <i>Human Mutation</i> , 2006, 27, 490-495.	2.5	90
188	Somatic Acquisition and Signaling of $\text{EMPH TYPE="ITAL">TGFBR1</EMPH>*6A}$ in Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1634.	7.4	87
189	Cancer Risk in Hereditary Nonpolyposis Colorectal Cancer Syndrome: Later Age of Onset. <i>Gastroenterology</i> , 2005, 129, 415-421.	1.3	338
190	Functional Significance and Clinical Phenotype of Nontruncating Mismatch Repair Variants of. <i>Gastroenterology</i> , 2005, 129, 537-549.	1.3	89
191	Screening for the Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer). <i>New England Journal of Medicine</i> , 2005, 352, 1851-1860.	27.0	1,237
192	Cancer Risk in Hereditary Nonpolyposis Colorectal Cancer Syndrome: Later Age of Onset. <i>Gastroenterology</i> , 2005, 129, 415-421.	1.3	309
193	Functional Significance and Clinical Phenotype of Nontruncating Mismatch Repair Variants of MLH1. <i>Gastroenterology</i> , 2005, 129, 537-549.	1.3	170
194	Mismatch Repair Gene PMS2. <i>Cancer Research</i> , 2004, 64, 4721-4727.	0.9	149
195	A Founder Mutation of the $\text{EMPH TYPE="ITAL">MSH2</EMPH>}$ Gene and Hereditary Nonpolyposis Colorectal Cancer in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 718.	7.4	75
196	Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques. <i>Human Mutation</i> , 2003, 22, 258-258.	2.5	87
197	Germline PTEN Promoter Mutations and Deletions in Cowden/Bannayan-Riley-Ruvalcaba Syndrome Result in Aberrant PTEN Protein and Dysregulation of the Phosphoinositol-3-Kinase/Akt Pathway. <i>American Journal of Human Genetics</i> , 2003, 73, 404-411.	6.2	283
198	Gi Polyposis and Glycogenic Acanthosis of The Esophagus Associated With Pten Mutation Positive Cowden Syndrome in The Absence of Cutaneous Manifestations. <i>American Journal of Gastroenterology</i> , 2003, 98, 1429-1434.	0.4	75

#	ARTICLE	IF	CITATIONS
199	The Founder Mutation MSH2*1906G→C Is an Important Cause of Hereditary Nonpolyposis Colorectal Cancer in the Ashkenazi Jewish Population. <i>American Journal of Human Genetics</i> , 2002, 71, 1395-1412.	6.2	118
200	A 39-bp Deletion Polymorphism in PTEN in African American Individuals. <i>Journal of Molecular Diagnostics</i> , 2002, 4, 114-117.	2.8	6
201	Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. <i>Human Mutation</i> , 2002, 19, 518-525.	2.5	63
202	Allele separation facilitates interpretation of potential splicing alterations and genomic rearrangements. <i>Cancer Research</i> , 2002, 62, 4579-82.	0.9	22
203	Germline Mutations in BMPR1A/ALK3 Cause a Subset of Cases of Juvenile Polyposis Syndrome and of Cowden and Bannayan-Riley-Ruvalcaba Syndromes*. <i>American Journal of Human Genetics</i> , 2001, 69, 704-711.	6.2	236
204	Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. <i>Lancet, The</i> , 2001, 358, 210-211.	13.7	210
205	Genetic Testing for Cancer Predisposition. <i>Annual Review of Medicine</i> , 2001, 52, 371-400.	12.2	103
206	Hereditary colorectal cancer: risk assessment and management. <i>Clinical Genetics</i> , 2001, 58, 89-97.	2.0	68
207	Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 15044-15049.	7.1	399
208	Epigenetic PTEN Silencing in Malignant Melanomas without PTEN Mutation. <i>American Journal of Pathology</i> , 2000, 157, 1123-1128.	3.8	254
209	Coming of Age in the Community Setting. <i>Oncology Issues</i> , 1999, 14, 14-15.	0.1	0
210	Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. <i>Journal of Clinical Oncology</i> , 1998, 16, 2417-2425.	1.6	435
211	Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. <i>Nature Genetics</i> , 1997, 17, 79-83.	21.4	630
212	Germline BRCA1 185delAG mutations in Jewish women with breast cancer. <i>Lancet, The</i> , 1996, 347, 1643-1645.	13.7	145
213	Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. <i>Nature Genetics</i> , 1996, 13, 126-128.	21.4	282
214	Universal tumor screening for lynch syndrome on colorectal cancer biopsies impacts surgical treatment decisions. <i>Familial Cancer</i> , 0, , .	1.9	1